Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
Provided By GlobeNewswire
Last update: Nov 13, 2024
― Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ―
― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents, and marketable securities; cash runway into at least 2027 ―
Read more at globenewswire.com
